1 Serum antibodies to surface proteins of *Chlamydia trachomatis* as candidate

2 biomarkers of disease: Results from the Baltimore Chlamydia Adolescent/Young

- 3 Adult Reproductive Management (CHARM) cohort.
- 4 Patricia X. Marques PhD^a, Handan Wand PhD^b, Melissa Nandy MSc^c, Chun Tan PhD^a,
- 5 Huizhong Shou BS^a, Mishka Terplan PhD^d, Katrina Mark MD^e, Rebecca M. Brotman
- 6 PhD^c, David P. Wilson PhD^f, Jacques Ravel PhD^{g,c}, Ru-ching Hsia PhD^h and <u>Patrik M.</u>

7 <u>Bavoil PhD</u>^a

- 8 Depts of ^aMicrobial Pathogenesis, ^dObstetrics & Gynecology, ^ePediatrics and
- ⁹ ^gMicrobiology and Immunology, ^cInstitute for Genome Science, and ^hElectron
- 10 Microscopy Core Imaging Facility, University of Maryland, Baltimore, Maryland, USA;
- ¹¹ ^bThe Kirby Institute, University of New South Wales, Sydney, Australia; ^fThe Burnet
- 12 Institute, Melbourne, Australia

Corresponding author: Patrik M Bavoil, Dept of Microbial Pathogenesis, University of
 Maryland School of Dentistry, 650 W. Baltimore St., Baltimore, MD 21201. Tel: 410 706
 6789; Fax: 410 706 0865; e-mail: pbavoil@umaryland.edu.

- 16
- 17 Word counts: Summary: 20; Abstract: 240; Text: 2,719
- 18 Number of references: 33; Number of figures: 2; Number of tables: 4
- 19 Conflicts of Interest and Source of Funding
- 20 The authors do not have a commercial or other association that might pose a conflict of
- 21 interest (e.g., pharmaceutical stock ownership, consultancy, advisory board
- 22 membership, relevant patents, or research funding).
- 23 Research reported in this publication was supported by the National Institute of Allergy
- and Infectious Diseases of the National Institutes of Health under award number
- 25 U19AI084044. The content is solely the responsibility of the authors and does not
- 26 necessarily represent the official views of the National Institutes of Health
- 27

28 Acknowledgements

- 29 The contributions of Esther Colinetti, Nyaradzo Longinaker, Anup Mahurkar and Dr. Ligia
- 30 Peralta to the development of the CHARM cohort are gratefully acknowledged.

32 Short Summary

Serological analysis of the CHARM cohort shows an association of the serum antibody
 response against OmcB and pelvic inflammatory disease.

35

36 Abstract

Background: We previously observed that the nine-member family of autotransported polymorphic membrane proteins (Pmps) of *Chlamydia trachomatis* is variably expressed in cell culture. Additionally, *C. trachomatis*-infected patients display variable Pmp-specific serum antibody profiles indirectly suggesting expression of unique Pmp profiles is an adaptive response to host-specific stimuli during infection. Here, we propose that the host response to Pmps and other outer surface proteins may correlate with disease severity.

Methods: This study tests this hypothesis using an ELISA that measures serum IgG
 antibodies specific for the nine *C. trachomatis* Pmp subtypes and four immunodominant
 antigens (MOMP, OmcB, GroEL, ClpP) in 265 participants of the *Chlamydia* Adolescent/Young Adult Reproductive Management (CHARM) cohort.

Results: More *C. trachomatis*-infected females displayed high Pmp-specific antibody levels (cut-off Indexes) than males (35.9-40.7% of females *vs.* 24.2-30.0% of males), with statistical significance for PmpC, F and H (P<0.05). Differences in Pmp-specific antibody profiles were not observed between *C. trachomatis*-infected females with a clinical diagnosis of pelvic inflammatory disease (PID) and those without. However, a statistically significant association between high levels of OmcB-specific antibody and a PID diagnosis (P<0.05) was observed.

Conclusions: Using antibody levels as an indirect measure of antigen expression, our results suggest that gender- and/or site-specific (cervix in females *vs.* urethra in males) stimuli control *pmp* expression in infected patients. They also support the possible existence of immune biomarkers of chlamydial infection associated with disease and underline the need for high resolution screening in human serum.

59

60 Keywords: Chlamydia trachomatis, polymorphic membrane proteins, surface proteins,

- 61 serology, ELISA, antibodies, pelvic inflammatory disease
- 62

63 INTRODUCTION

In 2018, more than 1.8 million cases of sexually transmitted Chlamydia trachomatis 64 infection in the United States were reported to the Centers for Disease Control and 65 Prevention (1). Chlamydial infections, which are often asymptomatic, can lead to pelvic 66 inflammatory disease (PID), a precursor of female infertility, ectopic pregnancy, and 67 68 chronic pelvic pain in 10-20% of infected women. Screening for C. trachomatis using nucleic acid amplification tests followed by treatment, can reduce the incidence of PID by 69 as much as 60% (2), suggesting that detection of an active chlamydial infection is an 70 71 effective means of reducing future sequelae. To fully control chlamydial disease however, host or chlamydial biomarkers that can discriminate between different clinical outcomes 72 early in, or during, infection remain highly desirable. 73

A panoply of secreted and/or surface proteins of *C. trachomatis* are thought to act 74 early in infection (3-6) as adhesins and/or invasins. These include the elementary body 75 76 (EB)-specific cysteine-rich outer membrane complex protein OmcB (5), the major outer membrane protein MOMP (OmpA) (7), and members of the polymorphic membrane 77 protein family (Pmps) (8). The late-expressed cysteine-rich protein OmcB was previously 78 79 suggested as a candidate adhesin for C. trachomatis (9), Chlamydia caviae (3), and more recently for Chlamydia pneumoniae (5). MOMP displays sequence-variable domains 80 81 defining 17 serovars categorized according to tissue tropism (A-C, ocular; D-K, urogenital; 82 L1-L3, inguinal lymph nodes), and was also proposed to function as an adhesin for C. trachomatis (10). The 9-member pmp gene family of C. trachomatis (Pmp subtypes A-I; 83 84 (11)) is predicted to be associated with tissue tropism (12). C. trachomatis PmpD-specific 85 antibody has been shown to dramatically reduce infection in vitro (6, 13). These properties

and the observed on/off switching of expression of the Pmps in cell culture (8, 14) suggest
that production of a specific Pmp subtype(s) may be required and/or selected for at
different sites or stages of infection. Consistent with variable expression in cell culture,
we have previously shown that all *C. trachomatis*-infected patients mount a strong
serologic response against different subsets of Pmps (15) with a suggested correlation
between disease (PID) and Pmpl antibody titer (15, 16).

The presence at the chlamydial surface of specific OmcB and MOMP types 92 combined with the expression of diverse PmpA-I profiles may provide the outer coat 93 94 diversity that is necessary for adherence to, internalization by and colonization of diverse mucosal sites. Since sites of infection may be associated with a spectrum of pathologies 95 ranging from none to severe, we further propose that distinct outer surface protein profiles 96 may also correlate with disease severity. Here we indirectly test these two linked 97 hypotheses using an antibody capture ELISA to evaluate the host response to OmcB and 98 99 MOMP, and as a surrogate for the expression of specific Pmp subtypes. We use serum samples from participants in the Chlamydia Adolescent/Young Adult Reproductive 100 Management (CHARM) cohort enrolled in the Baltimore, Maryland area. To address 101 102 site/gender specific expression, sera from C. trachomatis-infected men and women are compared. To address the possible link with disease severity, sera from women with a 103 104 lower genital tract C. trachomatis infection and a reported PID diagnosis are compared 105 with those without a PID diagnosis. Because of their previously reported association with disease in other studies, the *C. trachomatis* Heat Shock Protein GroEL (Hsp60) (17-19) 106 107 and the Caseinolytic protease P (ClpP) (19) are also included.

108

109 METHODS

110 CHARM cohort

The Chlamydia Adolescent & Young Adult Reproductive Management (CHARM) 111 cohort consists of 276 Chlamydia trachomatis-infected men and women recruited 112 between September 2010 and December 2013 in the Baltimore area (Table 1). CHARM 113 114 inclusion and exclusion criteria, informed consent, treatment, data and specimens collected at entry and at intervals, follow-up activities, and statistical analyses were 115 published independently (20). CHARM (HP-00042320) was reviewed and approved by 116 117 the Institutional Review Board of the University of Maryland Baltimore. For the purpose of this study, blood was collected without additives at enrollment and prior to antibiotic 118 treatment. After centrifugation, serum samples were stored at -20°C until analyzed. PID 119 diagnosis was based on the minimum clinical criteria (cervical motion tenderness, uterine 120 tenderness or adnexal tenderness) as set by the Centers for Disease Control and 121 Prevention (21). 122

123

124 Recombinant polypeptides

The predicted passenger domains of PmpC, D, E, F, H and I, smaller fragments of PmpA (*pmpA-F2*), PmpB (*pmpB-F1* and *pmpB-F2*) and PmpG (Figure 1) (15), rMOMP rGroEL, rOmcB and rClpP (from *C. trachomatis* serovar D; kindly provided by Dr. Guangming Zhong) were expressed in *E. coli* BL21(DE3) and purified as indicated in Table S1 (*Supplemental Digital Content 1 listing characteristics and purification conditions of the recombinant polypeptides*).

Insoluble polypeptides (all except rGroEL) were solubilized overnight at 42°C in 8 M
urea/10 mg/ml Octyl beta-D-glucopyranoside (OGP) in buffer (50 mM Tris-HCl, pH 8/1
mM EDTA/1 mM DTT), dialyzed against 0.01% OGP and affinity purified (*Table S1, in Supplemental Digital Content 1*).

Purification was monitored by SDS-PAGE and immunoblot (see Figure S1, in Supplemental Digital Content 1, which shows Expression and purification of all the recombinant proteins and peptides used in this study).

138

139 **ELISA**

Microplates PS (F-form; Greiner Bio-One North America, Inc.) coated with EBs 140 purified from 48h C. trachomatis serovar E cultures and C. pneumoniae AR39 (22) (see 141 Table S2 in Supplemental Digital Content 1, that lists the ELISA optimized conditions) or 142 purified recombinant polypeptides (see Table S2, in Supplemental Digital Content 1) were 143 incubated overnight at 4°C, washed with PBS-T and blocked with 2.5% milk. ELISA was 144 performed as described (23) using diluted CHARM sera (Table S2. Supplemental Digital 145 Content 1) and goat anti-human IgG peroxidase labeled antibody (1:2000 dilution; 100 146 µl/well; KPL, Inc.). Results were read in a Beckman DTX 880 plate reader (Beckman 147 Coulter, Inc.) at 450 and 620 nm (background). 148

Results obtained by ELISA were comparable to those previously obtained by immunoblot analysis and densitometry (15) (not shown), thus supporting the validity of results obtained by either method. ELISA results generated with GST•tagged and His•tagged OmcB were positively correlated (p<0.001; *see Figure S2, in Supplemental*

Digital Content 1, a graphic of the correlation between G-OmcB and H-OmcB), further
validating the ELISA.

155

156 Statistical analysis

157 Chi-squared test was used to compare the demographic, sexual behavior and 158 biological factors of the study groups. Median and inter-quartile ranges were used to 159 describe continuous variables. A non-parametric test was used to compare the median 160 by gender.

Antibody levels defined as the cut-off Indexes for rPmpA to I, rClpP, rHsp60, 161 rMOMP, rOmcB and C. trachomatis purified EBs were used as categorical variables and 162 split into tertiles. The first tertile cut-point represented the lower, while the third tertile 163 represented the higher cut-off indexes. Logistic regression models were then used to 164 determine the association between cut-off indexes in the first and third tertiles 165 166 (highest/lowest) and PID diagnosis (outcome). Unadjusted and adjusted Odds Ratios (ORs) and their 95% confidence intervals (CIs) were calculated. In adjusted analysis, 167 results were presented after accounting for potential confounding effects of age, 168 169 Trichomonas vaginalis infection and a diagnosis of bacterial vaginosis (BV) based on Amsel's criteria (24). 170

171 All analyses were performed using Stata 12.0 (College Station).

172

173 **RESULTS**

174 Demographics and sexual behavior in the CHARM cohort

A total of 265 participants (120 males, 45.3% and 145 females, 54.7%) of the 175 CHARM cohort were included in the study. The overall median age of the study population 176 was 19.5 years old (IQR: 17-21). Males were more likely to be older (median: 20.2 years, 177 178 IQR: 18-22) compared to women (18.9 years, IQR: 17-21 respectively) (p=0.0047). Table 1 compares demographic data, sexual behavior, sexual history and past and current 179 diagnosis of sexually transmitted infections (STIs) in men and women of the CHARM 180 181 cohort (20). Most of the study population reported having first vaginal intercourse before age 13 years (84.2%). Females were more likely to report a sexual debut before age 13 182 years (86.7 females vs. 77.5%, males, p=0.007). The majority of the participants (64.5%) 183 reported having 6 or more lifetime sexual partners. Male participants were more likely 184 than females to report 6+ sexual partners (53.1% females vs. 78.3% males, p<0.001). 185 There were no significant differences reported for receptive oral or anal sex based on 186 gender. Of the 145 CHARM female participants whose samples were analyzed by ELISA, 187 126 (86.9%) were heterosexual, one (0.7%) was homosexual and 18 (12.4%) were 188 189 bisexual. Thirty seven (25.5%) reported receptive anal sex. Of the CHARM 120 male participants, 105 (87.5%) were heterosexual, 9 (7.5%) were homosexual and 6 (5%) 190 191 bisexual. Thirteen (10.8%) reported receptive anal sex. Overall, 12.0% of the participants 192 reported condom use in the last 3 months and females were significantly less likely to report having sex with partners who used condoms compared to males (7.6% females 193 194 vs. 17.5% males, p=0.014). Most of the CHARM participants were African Americans or 195 of Hispanic/Latino ethnicity.

196

Factors associated with pelvic inflammatory disease (PID) in the females of the CHARM cohort

Of the 145 CT+ female participants from the CHARM cohort, 33 (22.8%) were clinically diagnosed as having PID at the study visit (Table 2). We assessed associations between a PID diagnosis with various demographic and sexual risk factors. Participants self-reporting previous *T. vaginalis* infection (OR: 2.79, 95% CI: 1.15 – 6.80, pvalue=0.0230.025), and previous PID (OR: 19.82, 95% CI: 2.23 – 176.52, p-value=0.007) were more likely to be diagnosed with PID at study entry.

205

206 The serum Pmp-specific antibody profile of *C. trachomatis*-infected CHARM 207 participants is associated with gender

C. trachomatis and *C. pneumoniae* purified EBs and recombinant antigen ELISA were used to analyze serum antibodies (IgG) of 265 patients (145153 females and 120 males) from the CHARM cohort. Most participants had an antibody response against HrOmcB, H-rPmpC, G-rHsp60, and H-rPmpI with sensitivity above 85% (*Table S3, Supplemental Digital Content 1*). The antibody response against *C. pneumoniae* purified EBs was very low with only 3 samples (1.1%) with slightly elevated antibody levels.

Potential association between serum antibody levels (grouped in tertiles) and gender was investigated. Overall, when compared to males, a higher proportion of females were in the top tertile across all Pmps (35.9-40.7% for females vs. 24.2-30.0% for males; Table 3). Significant gender differences were observed for rPmps subtypes HrPmpC-N (39.3% vs. 25.8%, p=0.001 for females and males respectively), H-rPmpF-N

(36.6% vs 29.2%, p=0.020) and rPmpH-N (40.7% vs 24.2%, p=0.018). Trending statistical
significance was observed for G-rPmpA-F2 (39.3% vs. 25.8%, p=0.068), and H-rPmpEN (39.3% vs. 25.8%, p=0.063). For G-MOMP, a significant proportion of males were in
the lower tertile when compared to females (26.2% vs. 42.5%, p=0.011). Gender-based
differences were not detected for other recombinant peptides.

224

The serum OmcB-specific antibody response is associated with a clinical diagnosis of pelvic inflammatory disease (PID) in *C. trachomatis*-infected female

227 CHARM participants

High antibody levels against H-rOmcB (Figure 2; Table 4 and see S4, in 228 Supplemental Digital Content 1, showing associations between factors (in tertiles) 229 associated with PID diagnosis with tertiles calculated only for females; OR: 2.31, 95% CI: 230 0.72-7.46, p=0.160 and OR: 4.22, 95% CI: 1.37-13.01, p=0.012, respectively) were 231 232 significantly associated with a clinical diagnosis of PID. Similar results were obtained for G-rOmcB (Figure 2; Tables 4 and S4) associated with PID diagnosis with tertiles 233 calculated only for females; OR: 2.58, 95% CI: 0.87-7.63, p=0.087/second vs. first tertile, 234 235 OR: 2.56, 95% CI: 0.86-7.65, p=0.091/third vs. first tertile).

In contrast, antibodies to the other tested antigens were not individually associated
with PID with any statistical significance. Antibody levels for the second and third tertiles
were almost identical for Hsp60 and MOMP (Figure 2.). Similarly, antibody levels against
each of the Pmp subtypes were not significantly associated with PID, although the
response to H-rPmpI was borderline significant (Figure 2; OR: 2.52, 95% CI: 0.89-7.11,
p=0.075/first vs. second tertile). Interestingly, however, antibody levels against 8 of the 9

rPmp subtypes (all but H-rPmpF) were slightly higher in women without a clinical
diagnosis of PID, although none reached statistical significance individually. This
suggests a global negative association of antibodies against the Pmp family and upper
genital tract disease.

246 DISCUSSION AND CONCLUSIONS

An ELISA was developed to measure antibody levels against recombinant 247 polypeptides derived from the 9 C. trachomatis Pmps, the EB-specific OmcB, MOMP, 248 ClpP, and the stress response protein GroEL, in 265 chlamydia-positive male and female 249 participants of the CHARM cohort from the Baltimore area. All participants exhibited an 250 251 antibody response to C. trachomatis purified EBs and at least one of the Pmps. While female CHARM participants had proportionally higher antibody levels to all Pmps 252 compared to males, statistically significant gender differences were observed for 3 Pmps 253 254 (rPmpC, F and H). The higher antibody levels in females are consistent with previous reports of sex differences in antibody responses (reviewed in (25)). However, since C. 255 trachomatis infection in men and women is diagnosed at different sites (the cervix in 256 women and urethra in men), these findings are also consistent with the hypothesis that 257 different Pmps may be expressed differentially in different anatomical sites and/or 258 259 physiological environments.

Statistically significant differences in anti-Pmp antibody levels were not detected 260 when comparing female CHARM participants with or without a positive clinical diagnosis 261 262 for PID, indicating that the Pmp-specific antibody response is not significantly altered when the infection ascends to the upper genital tract compared to when it is limited to the 263 264 lower genital tract. In turn, this suggests that the expressed Pmp profile of C. trachomatis-265 infected women is independent of the site of infection along the reproductive tract. Although Pmp-based differences were not observed, CHARM participants with a clinical 266 267 PID diagnosis were more likely to have high antibody levels against OmcB than those 268 without. This is consistent with previous reports of OmcB being associated with CD8+ T

cell-mediated upper genital tract immunopathology (26). In contrast, antibody levels were
almost identical for GroEL and MOMP, suggesting that these antigens are not associated
with upper genital tract infection and PID, consistent with previous findings for GroEL (27)
and MOMP (28). Our study failed to confirm the reported association of ClpP-specific
antibodies with upper genital tract disease (19). However, this earlier study involved a
different end point (tubal factor infertility) and a smaller cohort.

Overall, the observation of different antibody responses to specific Pmp subtypes 275 in C. trachomatis-infected patients relative to gender and/or site of infection, while 276 277 compatible with the hypothesized site-specific expression of Pmps in the context of infection, falls short of providing indisputable evidence for it, and does not lend confidence 278 that these antigens are exploitable for sero-diagnosis. Multiple behavioral, immunological 279 and structural factors have historically confounded or limited serologic analyses of 280 chlamydial antigens for diagnostic purposes. For instance, potential cross-reactivity with 281 orthologous antigens owing to Chlamydia pneumoniae (29) or Chlamydia psittaci (30) 282 previous or concurrent infections, gender-associated differential immune responses (25), 283 co-infection with other STIs, repeat infection with C. trachomatis or concurrent infection 284 285 at multiple sites, as well as non-native structural features of recombinant antigens, are potential limitations of any approach toward reliable sero-diagnosis. Conversely, any 286 statistically significant serologic difference that is detectable above the background 'noise' 287 288 generated by these confounding factors and limitations should be exploitable as a diagnostic or prognostic tool. In this context, our findings that OmcB-specific serum 289 290 antibody levels were elevated in women with a PID diagnosis suggests that this antigen 291 is worthy of further study as a biomarker of upper genital tract disease. For instance, the

292 possibility of determining whether an asymptomatic C. trachomatis-infected woman is likely to develop or already has subclinical upper genital tract pathology (silent PID; (31)) 293 via a simple measurement of OmcB-specific antibody would be of great benefit to the 294 physician and ultimately to his/her patient. Although cross-reactive antibody responses 295 against C. pneumoniae OmcB have been reported (32), Gijsen et al. (33) also showed 296 297 that tubal pathology was more common in patients with both C. pneumoniae and C. trachomatis antibodies compared to patients with antibodies against OmcB from only one 298 Chlamydia species, further strengthening a role for this well-conserved chlamydial protein 299 300 in eliciting pathology.

301

In conclusion, our expanded analysis of the observed Pmp-specific antibody profile 302 variation in *C. trachomatis*-infected men and women of the CHARM cohort may reflect 303 the hypothesized differential expression of different Pmp profiles as a prerequisite or in 304 response to infection of distinct urogenital sites. However other possibilities exist that 305 suggest that these antigens may be impractical to use as serologic biomarkers. Our study 306 also revealed an association between a high OmcB-specific serum antibody level and a 307 308 PID diagnosis. This finding corroborates previous studies (18) and indicates that this protein may provide an exploitable discriminatory biomarker of disease severity during C. 309 trachomatis infection. 310

311 **REFERENCES**

- https://www.cdc.gov/std/stats18/default.htm. Sexually Transmitted Disease
 Surveillance 2018: CDC; 2018.
- Chlamydia. In: Services USDoHaH, ed. 2013 Sexually Transmitted Diseases
 Surveillance. Atlanta: Center for Disease Control and Prevention; 2013.
- 316 3. Ting LM, Hsia RC, Haidaris CG, Bavoil PM. Interaction of outer envelope proteins 317 of *Chlamydia psittaci* GPIC with the HeLa cell surface. Infect Immun. 318 1995;63(9):3600-8.
- Su H, Watkins NG, Zhang Y-X, Caldwell HD. *Chlamydia trachomatis*-host cell
 interactions: Role of the chlamydial major outer membrane protein as an adhesin.
 Infection & Immunity. 1990;58:1017-25.
- Moelleken K, Hegemann JH. The *Chlamydia* outer membrane protein OmcB is
 required for adhesion and exhibits biovar-specific differences in
 glycosaminoglycan binding. Mol Microbiol. 2008;67(2):403-19.
- Crane DD, Carlson JH, Fischer ER, et al. *Chlamydia trachomatis* polymorphic
 membrane protein D is a species-common pan-neutralizing antigen. Proc Natl
 Acad Sci U S A. 2006;103(6):1894-9.
- Baehr W, Zhang Y-X, Joseph T, et al. Mapping antigenic domains expressed by
 Chlamydia trachomatis major outer membrane protein genes. Proceedings of the
 National Academy of Science, U.S.A. 1988;85:4000-4.
- Carrasco JA, Tan C, Rank RG, Hsia RC, Bavoil PM. Altered developmental
 expression of polymorphic membrane proteins in penicillin-stressed *Chlamydia trachomatis*. Cell Microbiol. 2011;13(7):1014-25.

Fadel S, Eley A. *Chlamydia trachomatis* OmcB protein is a surface-exposed
 glycosaminoglycan-dependent adhesin. J Med Microbiol. 2007;56(Pt 1):15-22.

- Su H, Watkins NG, Zhang YX, Caldwell HD. *Chlamydia trachomatis*-host cell
 interactions: role of the chlamydial major outer membrane protein as an adhesin.
 Infect Immun. 1990;58(4):1017-25.
- Stephens RS, Kalman S, Lammel C, et al. Genome sequence of an obligate
 intracellular pathogen of humans: *Chlamydia trachomatis*. Science.
 1998;282(5389):754-9.
- Gomes JP, Nunes A, Bruno WJ, Borrego MJ, Florindo C, Dean D. Polymorphisms
 in the nine polymorphic membrane proteins of *Chlamydia trachomatis* across all
 serovars: evidence for serovar Da recombination and correlation with tissue
 tropism. J Bacteriol. 2006;188(1):275-86.
- Paes W, Dowle A, Coldwell J, Leech A, Ganderton T, Brzozowski A. The
 Chlamydia trachomatis PmpD adhesin forms higher order structures through
 disulphide-mediated covalent interactions. PLoS One. 2018;13(6):e0198662.
- Tan C, Hsia RC, Shou H, Carrasco JA, Rank RG, Bavoil PM. Variable expression
 of surface-exposed polymorphic membrane proteins in *in vitro*-grown *Chlamydia trachomatis*. Cell Microbiol. 2010;12(2):174-87.
- Tan C, Hsia RC, Shou H, et al. *Chlamydia trachomatis*-infected patients display
 variable antibody profiles against the nine-member polymorphic membrane protein
 family. Infect Immun. 2009;77(8):3218-26.
- 16. Taylor BD, Darville T, Tan C, Bavoil PM, Ness RB, Haggerty CL. The role of *Chlamydia trachomatis* polymorphic membrane proteins in inflammation and

- 357 sequelae among women with pelvic inflammatory disease. Infect Dis Obstet
 358 Gynecol. 2011;2011:989762.
- Peeling RW, Kimani J, Plummer F, et al. Antibody to Hsp60 predicts an increased
 risk for chlamydial pelvic inflammatory disease. J.Infect.Dis. 1997;175:1153-8.
- Wagar EA, Schachter J, Bavoil PM, Stephens RS. Differential human serologic
 response to two 60,000 molecular weight *Chlamydia trachomatis* antigens.
 J.Infect.Dis. 1990;162:922-7.
- Rodgers AK, Wang J, Zhang Y, et al. Association of tubal factor infertility with
 elevated antibodies to *Chlamydia trachomatis* caseinolytic protease P. Am J
 Obstet Gynecol. 2010;203(5):494 e7- e14.
- Mark KS, Brotman RM, Martinez-Greiwe S, Terplan M, Bavoil P, Ravel J.
 Chlamydia in adolescent/adult reproductive management trial study (CHARM):
 Clinical core protocol. Contemp Clin Trials Commun. 2019;16:100414.
- 370 21. https://www.cdc.gov/std/pid/stdfact-pid-detailed.htm. Pelvic Inflammatory
 371 Disease: CDC; 2020.
- 372 22. Mahony JB, Schachter J, Chernesky MA. Detection of antichlamydial
 373 immunoglobulin G and M antibodies by enzyme linked immunosorbent assay.
 374 Journal of Clinical Microbiology. 1983;18:270-5.
- Frikha-Gargouri O, Gdoura R, Znazen A, et al. Evaluation of an *in silico* predicted
 specific and immunogenic antigen from the OmcB protein for the serodiagnosis of
 Chlamydia trachomatis infections. BMC Microbiol. 2008;8:217.

- Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK.
 Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic
 associations. Am J Med. 1983;74(1):14-22.
- 25. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol.
 2016;16(10):626-38.
- Vlcek KR, Li W, Manam S, et al. The contribution of *Chlamydia*-specific CD8(+) T
 cells to upper genital tract pathology. Immunol Cell Biol. 2016;94(2):208-12.
- Ness RB, Soper DE, Richter HE, et al. Chlamydia antibodies, chlamydia heat
 shock protein, and adverse sequelae after pelvic inflammatory disease: the PID
 Evaluation and Clinical Health (PEACH) Study. Sex Transm Dis. 2008;35(2):129388
- Stothard DR, Boguslawski G, Jones RB. Phylogenetic analysis of the *Chlamydia trachomatis* major outer membrane protein and examination of potential
 pathogenic determinants. Infect Immun. 1998;66(8):3618-25.
- Baud D, Regan L, Greub G. Comparison of five commercial serological tests for
 the detection of anti-*Chlamydia trachomatis* antibodies. Eur J Clin Microbiol Infect
 Dis. 2010;29(6):669-75.
- 30. Dumke R, Schnee C, Pletz MW, et al. *Mycoplasma pneumoniae* and *Chlamydia*spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerg
 Infect Dis. 2015;21(3):426-34.
- Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amortegui AJ, Hillier SL.
 Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis.
 2005;32(7):400-5.

401	32.	Bas S, Muzzin P, Vischer TL. Chlamydia trachomatis serology: diagnostic value of
402		outer membrane protein 2 compared with that of other antigens. J Clin Microbiol.
403		2001;39(11):4082-5.
404	33.	Gijsen AP, Land JA, Goossens VJ, Leffers P, Bruggeman CA, Evers JL.

- 405 *Chlamydia pneumoniae* and screening for tubal factor subfertility. Hum Reprod.
- 406 2001;16(3):487-91.

408 Figure legends

FIGURE 1: Schematic representation of the Pmp proteins and recombinant 409 polypeptides used in this study. Structural features of Pmps are shown; Predicted 410 signal peptide using Signal 4.0 software (yellow), passenger domain (green), GGA[I/L/V] 411 (black bars) and FXXN (orange bars) tetrapeptide repeats and autotransporter domain 412 413 (red). Recombinant Pmp derivatives based on predicted hydrophilic and antigenic domains located within the Pmp passenger domain, expressed in GST-tag pGEX-2t 414 415 vector (GE Healthcare Biosciences) are shown in light purple (G-rPmpA-F1) and purple 416 (G-rPmpA-F2, G-rPmpB-F1 and G-rPmp-F2). Passenger domain recombinant proteins 417 expressed as inclusion bodies in His•tag pET30 (a or b) are in blue (H-rPmp(C to I)-N).

418

FIGURE 2: High cut-off index antibodies associated with a PID diagnosis. Sera from 153 female CHARM participants were analyzed by ELISA. Odds ratios (ORs) for PID positivity when a patient is in the second (black) or third (grey) tertile, compared to the first tertile are shown. The OR (95% confidence interval) was greater than 1 for G-rOmcB in both tertiles and H-rOmcB in the second tertile (* p<0.05) suggesting that high antibody cut-off indexes for this antigen were significantly associated with PID. Results for HrPmpI-N second tertile were borderline significant (\ddagger p=0.075).

426

427

429 Supplemental Digital Content 1.pptx:

430

431 Supplemental Digital Content 1. Table S1, which lists the characteristics and
 432 purification conditions of the recombinant polypeptides.

433

Supplemental Digital Content 1. Figure S1, showing Expression and purification of 434 all the recombinant proteins and peptides used in this study. A) Coomassie staining 435 of all recombinant proteins; 1: G-rPmpA-F2, 2: G-rPmpB-F1, 3: G-rPmpB-F2, 4 to 10: H-436 437 rPmp(C to I)-N, 11: G-rClpP, 12: G-rHsp60, 13: G-rMOMP, 14: G-rOmcB, 15: H-rOmcB and 16: GST only. B) Immunoblots. Primary antibodies: guinea pig anti-Pmp A to I (lanes 438 1-10), mouse anti-ClpP (provided by Dr. Guangming Zhong) (lane 11), rabbit anti-GroEL 439 (lane 12) and anti-OmcB (lanes 14-15) and goat anti-MOMP (LifeSpan BioSciences) (lane 440 13) and anti-GST (GE Healthcare Bio-Sciences) (lane 16); secondary antibodies: Alkaline 441 phosphatase (AP)-conjugated anti-guinea pig, -mouse (KPL, Inc.), -rabbit and -goat 442 (Sigma-Aldrich). Membranes were revealed with fluorescent alkaline phosphatase 443 substrate ECF (GE Healthcare Biosciences). *Apparent molecular weights of protein 444 445 bands are listed in Table S1.

446

447 **Supplemental Digital Content 1. Table S2,** listing ELISA optimized conditions

448

Supplemental Digital Content 1. Figure S2, Correlation between G-OmcB and H OmcB. OmcB recombinant protein was obtained from 2 different clones using GST•tag
 pGEX-2t vector (G-OmcB) and His•tag pET30a vector (H-OmcB). Positive correlation

452	between the ELISA results obtained with these 2 proteins was statistical significant
453	(0.7462, p<0.001).
454	
455	Supplemental Digital Content 1. Table S3, showing the ELISA results, sensitivity and
456	coefficient variation
457	
458	Supplemental Digital Content 1. Table S4 listing tertiles for females only (n=153)
459	
460	

Figure 1: Marques et al.





Figure 2. Marques et al.



TABLES:

TABLE 1: Demographics and sexual behavior compared between genders

	Overall	Male N=120 (%)	Female N=145 (%)	P-value ^a
Age, median (IQR)	19.5 (17-21)	20.2 (18-22)	18.9 (17-21)	0.0047 ^b
Age groups				0.001
≤20 years old	150 (56.60)	55 (45.83)	95 (65.52)	
>20 years old	115 (43.40)	65 (54.17)	50 (34.48)	
	Sexu	al history		
Age of sexual debut				0.007
<13 years old	223 (84.15)	93 (77.50)	130 (89.66)	
13+ years old	42 (15.85)	27 (22.50)	15 (10.34)	
Sexual partners lifetime				<0.001
<6 partners	94 (35.47)	26 (21.67)	68 (46.90)	
6+ partners	171 (64.53)	94 (78.33)	77 (53.10)	
Oral sex	233 (87.92)	109 (90.83)	124 (85.52)	0.186
Anal sex	79 (29.81)	41 (34.17)	38 (26.21)	0.159
Condom use in past 3 months	32 (11.99)	21 (17.50)	11 (7.59)	0.014
Self-re	ported STI and	reproductive health	n history	
Bacterial STI ^c	206 (77.74)	88 (73.33)	118 (81.38)	0.117
Viral STI ^d	27 (10.19)	9 (7.50)	18 (12.41)	0.188
Trichomonas vaginalis	N/A ^e	N/A	28 (19.31)	N/A
BV	N/A	N/A	15 (10.34)	N/A
PID	N/A	N/A	6 (4.14)	N/A
	Physicia	n assessment ^f		
PID	N/A	N/A	33 (22.76)	N/A
ST	I Diagnostic La	boratory tests (curi	rent)	
HIV	18 (6.79)	8 (6.67)	10 (6.90)	0.941

RPR/ syphilis	2 (0.75)	1 (0.83)	1 (0.69)	0.893
GC/ gonorrhoea	20 (7.55)	10 (8.33)	10 (6.90)	0.659

^aP-values from chi-square, unless otherwise indicated

^bP-values from Rank-sun Wilcoxon

^cgonorrhoea, chlamydia and syphilis

^dHPV, Herpes and HIV

N/A, not applicable, diagnosed in women only

PID assessment was performed by a physician following CDC criteria

TABLE 2: Association of demographic, biological and sexual behaviors in 33 women with a PID diagnosis

among the 145 women in the study

		Unadjusted ana	lysis	Adjusted analysis	
	Overall	Odd ratio (95% Cl)	p-value	Odd ratio (95% Cl)	p-value ^a
Age groups			0.796		0.523
≤20 years old	95 (65.52)	1		1	
>20 years old	50 (34.48)	1.11 (0.50, 2.50)		0.75 (0.35, 1.83)	
		Sexual history			
Age of sexual debut			0.135		0.326
<13 years old	107 (73.79)	1.89 (0.82, 4.35)		1.60 (0.63, 4.05)	
13+ years old	38 (26.21)	1		1	
Sexual partners			0.079		0.274
lifetime					
<6 partners	68 (46.90)	1		1	
6+ partners	77 (53.10)	2.07 (0.92, 4.67)		1.64 (0.67 4.00)	
Receptive oral sex	119 (82.07)	2.58 (0.72, 9.22)	0.144	2.00 (1.00, 1.00)	0.596
ever (vs. never)					
Anal sex ever	38 (26.21)	1.07 (0.45, 2.57)	0.874	0.89 (0.36, 2.24)	0.808
(vs. never)					
No condom use in past	134 (92.41)	N/A ^b	N/A	N/A ^b	N/A
3 months					
		Self-reported prior \$	STI		
Bacterial STI ^c	118 (81.38)	2.73 (0.77, 9.71)	0.121	2.19 (0.59, 8.22)	0.244
Viral STI ^d	18 (12.41)	0.97 (0.29, 3.16)	0.954	0.54 (0.14, 2.09)	0.373
Trichomonas vaginalis	28 (19.31)	2.79 (1.15, 6.80)	0.023	2.36 (0.89, 6.25)	0.083
BV	15 (10.34)	2.54 (0.83, 7.77)	0.101	2.19 (0.68, 7.04)	0.191
PID	6 (4.14)	19.82 (2.23, 176.52)	0.007	-	

STI Diagnostic Laboratory tests (current) ^c						
HIV	10 (6.90)	0.36 (0.04, 2.93)	0.338	0.25 (0.03, 2.32)	0.223	
GC/ gonorrhea	10 (6.90)	0.84 (0.17, 4.16)	0.829	1.00 (0.19, 5.20)	0.998	

^aP-values from logistic regression

^bNone of the female participants positive for PID used condoms

^cgonorrhoea and chlamydia (syphilis was not analyzed because it was only detected in 1 female)

^dHPV, Herpes and HIV

	Overall	Male N=122 (%)	Female N=145 (%)	P-value ^a
G-rPmpA-F2				0.068
<0.41	89 (33.58)	45 (37.50)	44 (30.34)	
0.41 – 1.04	88 (33.21)	44 (36.67)	44 (30.34)	
>1.04	88 (33.21)	31 (25.83)	57 (39.31)	
G-rPmpB-F1				0.586
<0.28	89 (33.58)	43 (35.83)	46 (31.72)	
0.28 - 0.69	88 (33.21)	41 (34.17)	47 (32.41)	
>0.69	88 (33.21)	36 (30.00)	52 (35.86)	
G-rPmpB-F2				0.417
<0.55	90 (33.96)	42 (35.00)	48 (33.10)	
0.55 – 2.40	87 (32.83)	43 (35.83)	44 (30.34)	
>2.40	88 (33.21)	35 (29.17)	53 (36.55)	
H-rPmpC-N				0.001
<8.75	89 (33.58)	54 (45.00)	35 (24.14)	
8.75 – 20.47	88 (33.21)	35 (29.17)	53 (36.55)	
>20.47	88 (33.21)	31 (25.83)	57 (39.31)	
H-rPmpD-N				0.195
<1.88	89 (33.58)	47 (39.17)	42 (28.97)	
1.88 – 4.10	88 (33.21)	38 (31.67)	50 (34.48)	
>4.10	88 (33.21)	35 (29.17)	53 (36.55)	
H-rPmpE-N				0.063
<6.13	89 (33.58)	46 (38.33)	43 (29.66)	
6.13 – 14.94	88 (33.21)	43 (35.83)	45 (31.03)	
>14.94	88 (33.21)	31 (25.83)	57 (39.31)	
H-rPmpF-N				0.020

TABLE 3: Chlamydia antigenic biomarkers compared between genders (categorized by tertiles)

89 (33.58) 88 (33.21)	51 (42.50)	38 (26.21)	
00 (22 21)			
00 (33.21)	34 (28.33)	54 (37.24)	
88 (33.21)	35 (29.17)	53 (36.55)	
			0.199
89 (33.58)	44 (36.67)	45 (31.03)	
88 (33.21)	43 (35.83)	45 (31.03)	
88 (33.21)	33 (27.50)	55 (37.93)	
			0.018
89 (33.58)	46 (38.33)	43 (29.66)	
88 (33.21)	45 (37.50)	43 (29.66)	
88 (33.21)	29 (24.17)	59 (40.69)	
			0.105
89 (33.58)	46 (38.33)	43 (29.66)	
88 (33.21)	42 (35.00)	46 (31.72)	
88 (33.21)	32 (26.67)	56 (38.62)	
			0.709
89 (33.58)	39 (32.50)	50 (34.48)	
88 (33.21)	38 (31.67)	50 (34.48)	
88 (33.21)	43 (35.83)	45 (31.03)	
			0.952
89 (33.58)	40 (33.33)	49 (33.79)	
88 (33.21)	39 (32.50)	49 (33.79)	
88 (33.21)	41 (34.17)	47 (32.41)	
			0.011
89 (33.58)	51 (42.50)	38 (26.21)	
88 (33.21)	32 (25.83)	57 (39.31)	
	89 (33.58) 88 (33.21) 88 (33.21) 89 (33.58) 88 (33.21) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58) 88 (33.21) 88 (33.21) 88 (33.21) 88 (33.21) 88 (33.21) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58) 88 (33.21) 89 (33.58)	89 (33.58) 44 (36.67) 88 (33.21) 43 (35.83) 88 (33.21) 33 (27.50) 89 (33.58) 46 (38.33) 88 (33.21) 45 (37.50) 88 (33.21) 29 (24.17) 89 (33.58) 46 (38.33) 88 (33.21) 29 (24.17) 89 (33.58) 46 (38.33) 88 (33.21) 29 (24.17) 89 (33.58) 46 (38.33) 88 (33.21) 32 (26.67) 89 (33.58) 39 (32.50) 88 (33.21) 38 (31.67) 88 (33.21) 43 (35.83) 89 (33.58) 40 (33.33) 88 (33.21) 39 (32.50) 88 (33.21) 39 (32.50) 88 (33.21) 39 (32.50) 88 (33.21) 39 (32.50) 88 (33.21) 41 (34.17) 89 (33.58) 51 (42.50)	89 (33.58) 44 (36.67) 45 (31.03) 88 (33.21) 43 (35.83) 45 (31.03) 88 (33.21) 33 (27.50) 55 (37.93) 89 (33.58) 46 (38.33) 43 (29.66) 88 (33.21) 45 (37.50) 43 (29.66) 88 (33.21) 29 (24.17) 59 (40.69) 89 (33.58) 46 (38.33) 43 (29.66) 88 (33.21) 29 (24.17) 59 (40.69) 89 (33.58) 46 (38.33) 43 (29.66) 88 (33.21) 29 (26.67) 56 (38.62) 88 (33.21) 32 (26.67) 56 (38.62) 89 (33.58) 39 (32.50) 50 (34.48) 88 (33.21) 38 (31.67) 50 (34.48) 88 (33.21) 38 (35.83) 45 (31.03) 89 (33.58) 40 (33.33) 49 (33.79) 88 (33.21) 39 (32.50) 49 (33.79) 88 (33.21) 39 (32.50) 49 (33.79) 88 (33.21) 39 (32.50) 49 (33.79) 88 (33.21) 41 (34.17) 47 (32.41) 89 (33.58) 51 (42.50) 38 (26.21)

G-rOmcB				0.830
<1.94	89 (33.58)	40 (33.33)	49 (33.79)	
1.94 – 4.44	88 (33.21)	42 (35.00)	46 (31.72)	
>4.44	88 (33.21)	38 (31.67)	50 (34.48)	
H-rOmcB				0.835
<7.00	89 (33.58)	38 (31.67)	51 (35.17)	
7.00 – 24.83	88 (33.21)	41 (34.17)	47 (32.41)	
>24.83	88 (33.21)	41 (34.17)	47 (32.41)	
Ct purified EBs ^b				0.308
<1.96	89 (33.58)	43 (35.83)	46 (31.72)	
1.96 – 5.22	88 (33.21)	43 (35.83)	45 (31.03)	
>5.22	88 (33.21)	34 (28.33)	54 (37.24)	

^aP-values from chi-square

^bChlamydia trachomatis serovar E purified EBs

TABLE 4: Assessing associations between the levels of the factors (in tertiles) associated with PID diagnosis (tertiles calculated only for females, described on Table S4)

Diamarkara	second vs first		third vs first	third vs first		
Biomarkers	Unadjusted Odds Ratio (95% CI)	p-value	Unadjusted Odds Ratio (95% CI)	p-value ^a		
G-rPmpA-F2	0.66 (0.26 – 1.67)	0.379	0.58 (0.22 – 1.50)	0.258		
G-rPmpB-F1	0.64 (0.24 – 1.67)	0.362	0.82 (0.33 – 2.08)	0.680		
G-rPmpB-F2	1.83 (0.70 – 4.75)	0.214	1.17 (0.43 – 3.19)	0.760		
H-rPmpC-N	0.92 (0.36 – 2.34)	0.855	0.81 (0.31 – 2.11)	0.667		
H-rPmpD-N	1.03 (0.41- 2.59)	0.954	0.71 (0.27 – 1.89)	0.494		
H-rPmpE-N	1.77 (0.70 – 4.47)	0.225	0.78 (0.28 – 2.18)	0.636		
H-rPmpF-N	0.71 (0.27 – 1.89)	0.494	1.03 (0.41 – 2.59)	0.954		
H-rPmpG-N	1.57 (0.63 – 3.89)	0.330	0.59 (0.21 – 1.68)	0.322		
H-rPmpH-N	0.66 (0.26 – 1.67)	0.379	0.58 (0.22 – 1.50)	0.258		
H-rPmpl-N	2.33 (0.88 - 6.16)	0.088	1.35 (0.48 – 3.77)	0.569		
G-ClpP	0.92 (0.37 – 2.29)	0.863	0.55 (0.21 – 1.49)	0.242		
G-rGroEL	1.48 (0.56 – 3.93)	0.429	1.48 (0.56 – 3.93)	0.429		
G-rMOMP	1.48 (0.56 – 3.93)	0.429	1.48 (0.56 – 3.93)	0.429		
G-rOmcB	2.95 (1.03 – 8.49)	0.045	2.66 (0.92 - 7.72)	0.072		
H-rOmcB	2.62 (0.83 – 8.21)	0.099	4.83 (1.61 – 14.47)	0.005		
Ct purified EBs ^b	1.52 (0.55 – 4.20)	0.415	2.11 (0.79 – 5.63)	0.135		
	second vs first		third vs first			
	Adjusted ^c Odds Ratio (95% CI)	p-value	Adjusted ^c Odds Ratio (95% CI)	p-value		
G-rPmpA-F2	0.68 (0.26 – 1.79)	0.432	0.76 (0.27 – 2.14)	0.606		
G-rPmpB-F1	0.80 (0.28 – 2.25)	0.668	0.98 (0.35 – 2.69)	0.962		
G-rPmpB-F2	2.00 (0.72 – 5.52)	0.181	1.01 (0.35 – 2.92)	0.983		
H-rPmpC-N	0.98 (0.36 – 2.66)	0.974	0.85 (0.31 – 2.33)	0.752		

H-rPmpD-N	1.07 (0.41 – 2.81)	0.892	0.86 (0.31 – 2.40)	0.774
H-rPmpE-N	2.21 (0.80 - 6.10)	0.128	1.06 (0.35 – 3.19)	0.922
H-rPmpF-N	0.77 (0.28 – 2.16)	0.622	1.38 (0.51 – 3.75)	0.529
H-rPmpG-N	1.96 (0.74 – 5.17)	0.175	0.68 (0.22 – 2.03)	0.486
H-rPmpH-N	0.74 (0.28 – 1.98)	0.551	0.71 (0.25 – 1.99)	0.510
H-rPmpl-N	2.52 (0.89 – 7.11)	0.081	1.77 (0.59 – 5.36)	0.310
G-ClpP	0.80 (0.31 – 2.11)	0.657	0.51 (0.18 – 1.45)	0.208
G-rGroEL	1.28 (0.47 – 3.49)	0.634	1.40 (0.51 – 3.87)	0.517
G-rMOMP	1.32 (0.48 – 3.63)	0.592	1.39 (0.50 – 3.85)	0.529
G-rOmcB	2.58 (0.87 – 7.63)	0.087	2.56 (0.86 – 7.65)	0.091
H-rOmcB	2.31 (0.72 – 7.46)	0.160	4.22 (1.37 – 13.01)	0.012
Ct purified EBs ^c	1.59 (0.56 – 4.57)	0.385	2.23 (0.80 - 6.24)	0.127

^a P-values from logistic regression

^b Chlamydia trachomatis serovar E purified EBs

^c Adjusted for age, sexual partners ever, *Trichomonas vaginalis* and Bacterial Vaginosis (BV)